Tucson, AZ, United States of America

Hongmin Li

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.0

ph-index = 1


Location History:

  • Glenmont, NY (US) (2022)
  • Tucson, AZ (US) (2023)

Company Filing History:


Years Active: 2022-2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Innovations by Hongmin Li: A Focus on Flaviviral Inhibition**

Introduction

Hongmin Li, an innovative inventor based in Tucson, Arizona, has made significant contributions to the field of antiviral research. With a total of two patents, he has developed compounds and methods aimed at inhibiting viral replication and treating flaviviral infections. His work is particularly relevant in the context of increasing global concerns regarding flavivirus outbreaks.

Latest Patents

Li's latest patents include groundbreaking research on compounds designed to inhibit viral replication. One highlighted disclosure revolves around a specific compound of formula (I) or its pharmaceutically acceptable salts, which demonstrates effectiveness against flavivirus infections. This includes methods for treating and preventing conditions resulting from infections such as Dengue, Zika, and West Nile viruses. Additionally, another patent focuses on pharmaceutical compositions with antiflaviviral activity utilizing well-regarded agents like niclosamide, temoporfin, and nitazoxanide to achieve desired antiviral effects.

Career Highlights

Throughout his career, Hongmin Li has collaborated with important institutions, notably Health Research, Inc., and the United States Department of Health and Human Services. His proficiency in developing novel antiviral treatments has placed him at the forefront of research tackling public health issues related to viral infections.

Collaborations

In his innovative journey, Li has collaborated with fellow researchers Zhong Li and Laura D Kramer. Their combined efforts have contributed to advancing the understanding and treatment of flaviviral infections, showcasing the importance of teamwork in scientific endeavors.

Conclusion

In conclusion, Hongmin Li's work in the field of antiviral research and development represents a vital step toward combating flavivirus infections. His patents and collaborative efforts not only provide promising therapeutic avenues but also emphasize the necessity of continued innovation in the healthcare sector. The implications of his research could potentially lead to significant advancements in public health and disease prevention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…